The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Subscribe To Our Newsletter & Stay Updated
